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OBJECTIVE: To evaluate the effects of interleukin-6 (IL-6) and erythropoietin (EPO) in experimental acute spinal
cord injury (SCI) in rats.
METHODS: Using standardized equipment, namely, a New York University (NYU) Impactor, a SCI was produced
in 50 Wistar rats using a 10-g weight drop from a 12.5-mm height. The rats were divided into the following
5 groups of 10 animals each: ‘‘Group EPO’’, treated with erythropoietin only; ‘‘Group EPO+ IL-6’’, treated with
both substances; ‘‘Group IL-6’’, receiving IL-6 administration only; ‘‘Group Placebo’’, receiving a placebo solution;
and ‘‘Group Sham’’, submitted to an incomplete procedure (only laminectomy, without SCI). All drugs and the
placebo solution were administered intraperitoneally for three weeks. The animals were followed up for
42 days. Functional motor recovery was monitored by the Basso, Beattie, and Bresnahan (BBB) scale on days 2, 7,
14, 21, 28, 35 and 42. Motor-evoked potential tests were performed on the 42nd day. Histological analysis was
performed after euthanasia.
RESULTS: The group receiving EPO exhibited superior functional motor results on the BBB scale. IL-6 administration
alone was not superior to the placebo treatment, and the IL-6 combination with EPO yielded worse results than did
EPO alone.
CONCLUSIONS: Using EPO after acute SCI in rats yielded benefits in functional recovery. The combination of EPO
and IL-6 showed benefits, but with inferior results compared to those of isolated EPO; moreover, isolated use of
IL-6 resulted in no benefit.
KEYWORDS: Interleukin-6; Erythropoietin; Spinal Cord Injuries; Central Nervous System/Injuries; Rats.
’ INTRODUCTION
The devastating deficits and disability caused by spinal
cord injuries (SCIs) are the target of researchers worldwide
who seek pharmaceutical, surgical or mechanical treatment
options (1) because this type of trauma most often affects
productive workers (2). The pharmacological treatments
explored in experimental and clinical trials are usually aimed
at avoiding the secondary medullary injury that follows the
initial mechanical trauma (1). High doses of methylpredniso-
lone have been criticized recently for their limited evidence of
benefit (3-5). Corticoids seem to cause important side effects
(3,6,7). Laboratories have been trying to fill the gap in
providing drugs such as estrogen, progesterone, erythropoie-
tin, and magnesium for further testing in clinical trials (5,8).
Erythropoietin hormone plays a role in red cell home-
ostasis and seems to improve metabolism in many tissues
(9). In rabbits (10) and rats (11,12), erythropoietin has shown a
protective effect against experimental ischemic spinal injury.
It likely reduces cell death by apoptosis and regulates the
inflammatory activity of cytokines (13), thereby promoting
angiogenesis (14), reestablishing vascular autoregulation
(15-17) and reducing lipid peroxidation (18). Significantly
better functional results have been obtained with erythro-
poietin compared to the control treatment in a recent
experimental trial (19), which, although appearing weeks
after the treatment started, allowed the authors to suggest
that there might be a possible mitigating effect of the
hormone on secondary SCI.
In addition to erythropoietin, other molecular mediators
of neuroaxonal growth and regeneration that have been the
focus of most studies are interleukins (ILs) 1, 2, 4, 6 and 10DOI: 10.6061/clinics/2019/e674
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and interferon-gamma (18,20,21). The roles of these T-cell
cytokines in injury-induced neural damage and repair are
complex, and their interaction has been investigated (22).
Researchers have been trying to obtain better axonal rege-
neration without excessive scarring, which could impair
axon growth. The use of interleukin in low dosages can result
in less scarring and better axonal regeneration (23), and IL-6
acts directly on Schwann cells (apparently the highest source
of Il-6 (24)), releasing glial fibrillary acid protein (GFAP),
which is necessary for neuronal regeneration (25).
While the results with erythropoietin seem promising,
there is still some controversy about the role of cytokines
as a therapeutic approach in SCI (26). Therefore, we aimed
to evaluate the functional, histological, and motor-evoked
potential (MEP) effects of both agents (namely, erythropoie-
tin and IL-6) on the treatment of SCI in rats. The hypothesis
was that there would be a synergistic effect between erythro-
poietin and IL-6 that could lead to neurological improvement
better than that yielded by the isolated drugs.
’ METHODS
Study design and ethics
This was an experimental study with rats, conducted in
the same university laboratory specialized in spinal cord
trauma as that in previous studies (19,27,28). The present
investigation followed all national and international guide-
lines and regulations for animal experimentation and pain
control. Furthermore, the university’s ethics committee
approved the study protocol.
In this study, we divided rats into five groups of ten
animals each. All rats in four of the groups underwent expe-
rimental SCI as described below, and each group received
one type of treatment or placebo. The fifth group underwent
laminectomy only, without SCI (the sham group).
Sample size and allocation
We based the sample size of 50 rats on other experiments
with spinal cord lesions using the same method proposed
here. This study randomized 50 rats into groups considering
possible losses during follow-up (8,19,27-32). A computer
sequence generator randomized the allocation. Rats had their
tails marked with different codes according to the allocation
group. After the experimental and therapeutic procedures,
we evaluated them for function, and the evaluators were
blind to the animal allocation because they did not know the
meaning of the tail codes. After euthanasia, a pathologist also
blinded to the animal allocation and the other evaluations
performed histological analyses of the spinal cord tissue.
We divided rats into the following five groups:
- ‘‘Group EPO’’ - undergoing a spinal cord lesion and
receiving 1,000 IU/kg of body weight of erythropoietin
(EPO) intraperitoneally, daily for three weeks;
- ‘‘Group EPO + IL-6’’ - undergoing a spinal cord lesion
and receiving the same dose of EPO plus 200 UI/100 g of
interleukin-6 (IL-6) intraperitoneally, daily for three weeks;
- ‘‘Group IL-6’’ - undergoing a spinal cord lesion and
receiving only IL-6 at the same dose above, during the same
time;
- ‘‘Group Placebo’’ - undergoing spinal cord lesion and
receiving saline intraperitoneally daily for three weeks;
- ‘‘Group Sham’’ - undergoing laminectomy only, without a
spinal cord lesion or any therapeutic procedure.
We administered the drugs immediately after the spinal
cord contusion. After the experiments, the rats remained in
the cages for 48 hours and then underwent a functional
evaluation using the Basso, Beattie, and Bresnahan (BBB) (33)
scale at seven specific time points, an MEP exam (on day 42
after the lesion) and a histological evaluation after euthanasia.
Animal care and pain control
In this study, we used male, young adult Wistar rats
weighing 340 to 450 g, all from the same bioterium. The rats
were all similar regarding size, weight and health conditions,
and all had a good health status and healthy skin on visual
inspection. Furthermore, they all presented normal motricity
on the baseline (21 points in the BBB scale).
Animals were stimulated to move before the experiment so
that they became accustomed to the handling by researchers.
They were maintained in cages measuring 60 cm x 40 cm, up
to five animals each cage, with water and feeding ad libitum.
The laboratory had a controlled temperature (25oC).
We excluded rats from the study if they had a persistent
infection (present after 10 days of antibiotic therapy), if they
lost more than 10% of their body weight after the spinal cord
lesion, if they died immediately after the spinal cord lesion,
or if the lesion was not effective (and the rat had normal
motricity after the lesion). Autophagia or mutilation behaviors
during the follow-up period were also exclusion criteria.
Rats underwent spinal cord lesions under anesthesia using
100 mg/kg of ketamine and 5 mg/kg of xylazine. For local
anesthesia, we used lidocaine hydrochloride with epinephr-
ine. Anesthesia was confirmed by the absence of corneal
and tail reflexes and hind paw reactions at compression (34).
The anesthetic agents took effect after 5min and lasted for at
least 2 h. For MEP evaluations, we administered pentobarbi-
tal (55-75mg/kg) intraperitoneally and used the lethal dose
of 140 mg/kg, followed by potassium chloride intravenously
for euthanasia, on day 42.
After laminectomy, spinal cord lesioning and suturing,
the animals received an antibiotic (cephazolin, 2 mg/100 g
intraperitoneally, single dose) and pain medication (tramadol,
hydrochloride, 5 mg/100 g intramuscularly for five days and
meloxicam, 2 mg/kg, once daily for seven days). The bladder
of each rat was emptied by manual pressure daily. Blood
detected in the urine was an indication for levofloxacin use
(2.5 mg/100 g for 10 days) due to urinary infection. Persistent
infection after 10 days was an indication for study exclusion
and immediate euthanasia to prevent transmission to other rats.
Experimental procedures
Once anesthetized, the animals were trichotomized in the
dorsal region for the laminectomy procedure, according to
the methods standardized in the laboratory (28,30-32,34). An
incision was made in the skin, following the medial dorsal
line, reaching the aponeurotic and muscular planes, and
exposing the posterior vertebral arches from T8 to T12, with
subperiosteal dissection of spinous processes and laminae
from T9 to T11. Hemostasis was performed using a bipolar
coagulator when needed. The spinous process and laminae
of the T10 vertebra were removed using a bone rongeur,
together with the distal half of the T9 spinous process, so
that the spinal cord was exposed. This procedure allowed
the positioning of the tip of an NYU Impactor device for
experimental spinal cord lesions. The NYU Weight-Drop
Impactor (New York University Medical Center, New York,
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NY, USA) (33) was used to produce a controlled moderate
spinal cord lesion at the thoracic level (T8-T11) in all rats,
except those in Group Sham.
A drop of a 10-g rod from a height of 12.5 mm was used
to produce a moderate spinal cord lesion, as described
previously (8,19,28). We then washed the lesion site with
saline and sutured the muscles, fascia, and skin using nylon
monofilaments (2.0).
Functional evaluation
Two trained researchers simultaneously evaluated motri-
city using the BBB scale, which ranges from zero (no
movement) to 21 points (normal motricity), and they were
blind to each other’s scoring and to the animal allocation.
When there was disagreement in their registries, we recorded
the lowest score for analysis. This evaluation with the BBB
scale took place on days 2, 7, 14, 21, 28, 35 and 42 after the
spinal cord lesion.
Neurophysiological evaluation
The MEP exam was used to evaluate the muscle response
to electrical stimulation 42 days after the spinal cord lesion.
Under the anesthetic procedure described above, the rat was
shaved, and electrodes were positioned in the head and
limbs as described previously (18,35). The electrodes had
paired needles with a fixed distance, and the muscles chosen
were the distal extensors of the anterior and posterior limbs.
The following parameters were used for the records: SWEEP
SPEED: 2.0 ms/div and GAIN: 2 mV. All MEP exams were
conducted by the same evaluator, who was blind to the
animal allocation. Latency and amplitude values were
recorded for each rat.
Histological evaluation
The animals were sacrificed after the MEP exam, and
spinal cords were removed from C3 to T10 for histological
evaluation. The tissues were identified and fixed in 10%
formalin, and the 2-mm fragments were bathed in alcohol,
diaphanized in xylol and embedded in liquid paraffin. The
paraffin blocks were then cut into 5-mm-thick sections using a
Leica microtome (MR 2055, Wetzlar, Germany). The sections
were placed on glass slides, bathed in saline and stained with
hematoxylin and eosin.
The same pathologist evaluated all slides for necrosis,
hemorrhage, hyperemia, nerve degeneration and cellular
infiltrates, according to the following scale: zero, indicating
absence; 1 point, representing a mild presence; 2 points,
indicating a moderate presence; and 3 points, designating a
strong presence of the feature. This pathologist was blind to
the group allocation.
The slides were also fixed in osmium tetroxide solution
and stained with 2% toluidine blue at 1% to allow the
regenerated axon neuron count. The pathologist chose two
areas with a good representation of cells from each section
(cranial and caudal, with 40x magnification) and considered
neurons with diameters greater than 15 mm for counting. The
software Sigma Scan Pro 5.0 (Sigma, San Jose, CA, USA) was
used for neuron counting.
Outcomes and statistical analysis
The primary outcome evaluated in this study was the BBB
score on day 42. MEP amplitude and latency results and
histological results (scoring and neuron counts) were
considered secondary outcomes. As the results had a Gaussian
distribution, we used parametric and nonparametric tests.
We employed analysis of variance (ANOVA) or the Kruskal-
Wallis test for the comparison of groups. Student’s t and
Mann-Whitney tests with Bonferroni correction were used
for comparisons between groups. For the paired compar-
ison over time, repeated measures ANOVA or the Friedman
test was employed.
We used the software SPSS 20.0 for Mac for the statistical
analysis and considered a difference as significant when type
I error was equal to or less than 0.05.
’ RESULTS
During the six weeks of the study, all rats were equally
taken care of according to the protocol described above, with
pain control and antibiotic therapy. Nevertheless, four rats
died. In Group EPO, rat #8 died of infection in the third
week, and rat #10 was excluded in the fourth week due to
autophagic behavior. In Group EPO + IL-6, we had to
exclude rat #5 for autophagy in the sixth week. In Group
Placebo, rat #9 died of an infection in the third week. In
Group IL-6 and Group Sham, there was no death.
Functional analysis
Table 1 presents a descriptive analysis of the BBB scores.
The difference between the moments of the evaluation was
Table 1 - Mean and standard deviation (SD) for the Basso,
Beattie and Bresnahan (BBB) scores (mean and SD) in each group
in the seven moments of evaluation.
Group Mean SD
2nd day EPO 0.375 0.619
EPO + IL-6 0.167 0.383
IL-6 0.300 0.470
Placebo 0.278 0.574
Sham 21 0
7th day EPO 1.063 1.878
EPO + IL-6 0.444 0.511
IL-6 0.550 0.759
Placebo 1.611 2.725
Sham 21 0
14th day EPO 4.688 1.815
EPO + IL-6 3.611 1.195
IL-6 3.850 1.899
Placebo 4.722 2.080
Sham 21 0
21st day EPO 7.563 2.250
EPO + IL-6 6.444 1.885
IL-6 6.100 2.337
Placebo 5.889 2.139
Sham 21 0
28th day EPO 11.250 2.670
EPO + IL-6 9.667 2.376
IL-6 7.050 2.012
Placebo 7.111 2.323
Sham 21 0
35th day EPO 12.750 2.206
EPO + IL-6 11.667 2.543
IL-6 8.450 2.438
Placebo 7.444 2.331
Sham 21 0
42nd day EPO 14.250 1.949
EPO + IL-6 12.778 1.592
IL-6 8.950 1.959
Placebo 8.333 1.940
Sham 21 0
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significant for all five groups (p=0.001 for Group EPO and
p=0.0001 for the others; Friedman test). Because it did not
suffer SCI, Group Sham received a score of 21 in all
evaluations (indicating the maximum score and normal
function).
Figure 1 illustrates the evolution of BBB scores of the five
groups over the seven (2nd, 7th, 14th, 21st, 28th, 35th and 42nd
day) assessment periods. There was a significant difference
between Group EPO and Group EPO + IL-6 (po0.001).
Additionally, there was a significant difference between
Group EPO + IL-6 and Group IL-6 (po0.0001). Although
it seemed more important for Group IL-6 than for Group
Placebo, this difference was not statistically significant
(p41). The values of the BBB scale in Group Sham were
constant, as expected.
Evoked potential analysis
The results of the MEP evaluation in 46 rats are
shown in Table 2, containing the mean and standard
deviation values of latency and amplitude. The mean
values of amplitude and latency per group are presented
in Figures 2 and 3, respectively. Table 3 compares the mean
amplitude and latency values, according to the p-values,
by group.
Histological analysis
There were statistically significant differences (Kruskal-
Wallis test) among the five groups for all histological variables
(necrosis, hemorrhage, hyperemia, degeneration and infiltrate),
except for hemorrhage. As the Kruskal-Wallis test showed a
difference among all groups altogether, we applied the Mann-
Whitney test for pairwise comparisons. Table 4 shows these
results. Groups EPO and EPO + IL-6 were similar. Likewise,
the neuron count analysis showed no significant differences
between groups (Bonferroni test), except for obvious differ-
ences from the Sham group.
’ DISCUSSION
In our study, compared to treatment with placebo or EPO,
the administration of IL-6 after acute SCI did not yield any
significant differences in neurological recovery. The associa-
tion of EPO with IL-6 seemed to have a negative effect on the
EPO action since the analyses showed that EPO was better
Figure 1 - Evolution of the scores on the Basso, Beattie and Bresnahan (BBB) motor scale of the five groups over the seven (2nd, 7th, 14th,
21st, 28th, 35th and 42nd days) evaluation periods. The blue line indicates the results of Group EPO, the green line indicates the evolution
of Group EPO+ IL-6, the orange line indicates the evolution of Group IL-6, and the purple line indicates Group Placebo. The black line
represents Group Sham, which did not suffer spinal cord injury (SCI) and therefore remained unchanged with respect to function.
Table 2 - Motor-evoked potential (MEP) results: means and
standard deviations (SDs) for latency and amplitude for the
hindlimbs of the animals in each group.
Group Mean SD
Latency EPO 12.038 2.72
EPO + IL-6 12.135 1.62
IL-6 11.842 2.25
Placebo 6.108 2.33
Sham 20.791 4.93
Amplitude EPO 126.858 26.18
EPO + IL-6 103.959 20.66
IL-6 49.356 4.41
Placebo 34.413 3.09
Sham 189.064 6.76
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Figure 2 - Mean amplitude in the motor-evoked potential (MEP) exam of hindlimbs for each group.
Figure 3 - Mean latency in the motor-evoked potential (MEP) exam of hindlimbs for each group.
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than EPO plus IL-6 and that this combination was better than
IL-6 or placebo.
IL-6 plays a key role in traumatic central nervous system
(CNS) injuries, and it is one of the most common proin-
flammatory cytokines in the acute and subacute phases after
trauma to the spinal cord, actively participating in secondary
injury to the spinal nervous tissue (36). The occurrence of
an injury is accompanied by a substantial increase in the
concentration of IL-6 and other proinflammatory cytokines.
This elevation starts approximately 30 minutes after the
trauma and lasts for approximately five hours. After this
period, there was a decline in the expression of these media-
tors before the appearance of macrophages and neutrophils
24 hours after the trauma. This early peak suggests that IL-6
and other proinflammatory cytokines are mainly produced
by cells of the CNS itself (microglia and neurons) rather than
by infiltrating leukocytes as originally thought (37). Experi-
mental studies corroborate this theory, showing that in
the presence of a traumatic CNS injury, the IL-6 receptor is
present in oligodendrocytes and neurons and that IL-6-
induced neuritis promotes increased neuronal survival by
inducing the production of neurotrophic factors (38,39).
These pieces of evidence prompted us to investigate IL-6 as a
possible pharmacological treatment in SCI.
However, the role of IL-6 in the inflammatory response
after SCI is still not well explained. Perhaps this interleukin
functions as both a neurotrophic factor and a cytotoxic factor.
There are some explanations for these seemingly contra-
dictory functions. This initial elevation in the expression of
IL-6 and other inflammatory cytokines in the first hours
after SCI may be damaging due to overproduction of these
mediators, and there is a rather narrow window for the
difference between benefit and toxicity (40). In vitro studies
have shown that cells need to be intact, without traumatic
injury, to produce the IL-6 neurotrophic effects, and this
situation may not occur in vivo (37). In fact, the cellular
activities of cytokines are complex and subject to variations
in concentration, receptors, subtypes and time of adminis-
tration (41,42). Studies show that the injection of cytokines
into the spinal cord four days after injury promotes a
decrease in the activation of microglia, a reduction in the
recruitment of circulating macrophages and tissue loss.
However, when these same cytokines are given one day
after the injury, the posttraumatic inflammatory response
and tissue loss are better (43,44).
To evaluate tissue characteristics, we included a histo-
pathological analysis of the spinal cord of the animals with
SCI in our study to assess the degree of cellular damage and
evidence of neuronal morphological alterations. However,
previous experiences in our laboratory have suggested that
hematoxylin and eosin staining for histological evaluation
of the spinal cord may be not sensitive enough to detect
significant differences. This is why we opted to evaluate
neuronal cell counting also, but in our study, there was no
significant difference in cell counts between groups. One of
the possible explanations for this finding is the choice to
induce a moderate lesion in this experimental study (45): we
used a height of 12.5 mm for the weight drop on the spinal
cord of the rats. This choice prioritized functional changes
more than morphostructural changes. Therefore, functional
analyses were our priority.
The functional analysis using the BBB scale showed that
the rats submitted to treatment with erythropoietin (Group
EPO) presented significantly better results than the rats
from other groups at the end of the six weeks. In the neuro-
physiological analysis through the MEP, there was also
no significant difference in the mean values of amplitude
between Groups EPO and EPO + IL-6. Group Sham had the
highest mean latency, which we considered to be counter-
intuitive because the animals in this group did not suffer SCI
and presented a normal score on the BBB functional scale. We
did not take into consideration the mean latency results
obtained because the literature shows that this parameter can
be influenced by the small size of the animal, and even a
minimal amount of preserved nerve fibers can transmit the
electric impulse, biasing the interpretation (46).
EPO has a neuroprotective role in the ischemic and
traumatic lesions of the CNS, as demonstrated in experimental
Table 3 - Comparison of mean latency (LAT) and mean
amplitude (AMP) in the motor-evoked potential (MEP) exam:
p-values.
Group p: AMP mean (mA) p: LAT mean (ms)
EPO versus EPO + IL-6 o1.000 o1.000
EPO versus IL-6 o0.003 o1.000
EPO versus Placebo o0.001 o0.001
EPO versus Sham o0.031 o0.001
EPO + IL-6 versus IL-6 o0.071 o1.000
EPO + IL-6 versus Placebo o0.009 o0.001
EPO + IL-6 versus Sham o0.001 o0.001
IL-6 versus Placebo o1.000 o0.001
IL-6 versus Sham o0.001 o0.001
Placebo versus Sham o0.001 o0.001
Table 4 - Pairwise group comparison of the results from the histological analysis: p-values.
p values
Groups Necrosis Bleeding Hyperemia Degeneration Infiltrate
EPO versus EPO + IL-6 0.114 0.071 0.536 0.963 0.423
EPO versus IL-6 0.408 0.536 0.161 0.055 0.965
EPO versus Placebo 0.236 0.918 0.758 0.481 0.541
EPO versus Sham 0.016 0.364 0.002 0.001 0.173
EPO + IL-6 versus IL-6 0.053 0.315 0.447 0.028 0.400
EPO + IL-6 versus Placebo 0.063 0.222 0.666 0.387 0.094
EPO + IL-6 versus Sham 0.661 0.356 0.0001 0.0001 0.447
IL-6 versus Placebo 0.720 0.780 0.133 0.156 0.549
IL-6 versus Sham 0.004 0.853 0.0001 0.0001 0.143
Placebo versus Sham 0.006 0.604 0.0001 0.0001 0.017
po0.05.
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trials (10-12). It acts by reducing the inflammatory response,
promoting angiogenesis, inhibiting lipid peroxidation and
modulating the antiapoptotic response (12,47,48). In our study,
over the weeks, Group EPO presented higher scores in the
evaluation by the BBB scale. This improvement allows us to
strengthen the hypothesis of the role of EPO as a neuropro-
tective agent (46). We believe that the use of EPO in the
treatment of acute SCI should be further investigated and
that other variables, such as dose, time of treatment, route
of administration, synergism with other drugs, and clinical
applicability should be addressed.
The results of the use of erythropoietin in acute medullary
lesions in rats are also conflicting in the literature (19,46,49).
This controversy may perhaps be explained by differences
in study designs, pertaining to the dose, time of treatment,
animal race or strain and patterns of the medullary lesion.
Additionally, some mechanisms of erythropoietin action
are still unknown. We can infer that the results of Group
EPO+ IL-6 were inferior to those of Group EPO because the
presence of IL-6 negatively modified the action of EPO. As
previously mentioned, interleukins have dynamic effects that
change between neuroprotection and neurotoxicity. These
complex and unknown mechanisms were not the focus of
this study. However, our results allow us to suppose that
these variations may be very subtle because although the
BBB scores for Group EPO+ IL-6 were lower than the scores
for Group EPO, the BBB scores in Group IL-6 were not
inferior to those of Group Placebo. This finding suggests that
there may be some antagonism between IL-6 and EPO, rather
than neurotoxicity. Additionally, the histological evaluation
and the MEP exams did not show any significant differences
between Groups EPO and EPO + IL-6. Further studies are
needed to clarify these gaps better.
’ CONCLUSION
The administration of erythropoietin after experimental
SCI in rats showed benefits for motor recovery. The combi-
nation of erythropoietin and IL-6 yielded benefits, but with
lower results than erythropoietin alone. Isolated use of IL-6
showed no benefit after experimental SCI in rats.
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